top of page
Browse by category
Search
FDA accepts Rhythm’s sNDA for setmelanotide in acquired hypothalamic obesity
The FDA has accepted for filing the Rhythm Pharmaceuticals’s supplemental New Drug Application (sNDA) for setmelanotide seeking approval...
Rhythm’s Bivamelagon achieved statistically significant and clinically meaningful reductions in BMI in patients with hypothalamic obesity
Rhythm Pharmaceuticals’ bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, achieved...
TRANSCEND trial meets primary endpoint with -19.8% placebo-adjusted BMI reduction in patients with acquired hypothalamic obesity
Rhythm Pharmaceuticals has announced positive topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a...
Rhythm gains expanded indication for IMCIVREE (setmelanotide) for patients as young as 2 years old
Rhythm Pharmaceuticals has received an expanded indication for IMCIVREE (setmelanotide) to include children as young as 2 years old to...
Rhythm gains Health Canada Approval of IMCIVREE setmelanotide injection for weight management
Health Canada has approved Rhythm Pharmaceuticals’ IMCIVREE (setmelanotide solution for subcutaneous injection) for weight management in...
Browse by tag
bottom of page